Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Goss, Glenwood D

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep 2013 - 3320-6 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1527-7755

10.1200/JCO.2013.51.1816 doi


Aged
Antineoplastic Agents--adverse effects
Carcinoma, Non-Small-Cell Lung--drug therapy
Chemotherapy, Adjuvant
Disease-Free Survival
Double-Blind Method
Female
Gefitinib
Humans
Lung Neoplasms--drug therapy
Male
Neoplasm Staging
Placebos
Prospective Studies
Quinazolines--adverse effects
Survival Rate
Treatment Outcome